| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08:07 | Oppenheimer downgrades Amdocs stock rating on weak guidance | ||
| 08:07 | Jefferies downgrades Haleon stock rating on margin concerns | ||
| 08:07 | JPMorgan upgrades Archer Daniels stock rating on valuation | ||
| 08:07 | Truist upgrades Edwards Lifesciences stock rating on trial results | ||
| 08:06 | Zaptec Q3 2026 slides: revenue surges 39%, EBITDA nearly triples | ||
| 08:06 | Nephrocare Q2 FY27 slides: 24% revenue growth, international push | ||
| 08:06 | Vijaya Diagnostic Q2 FY27 slides: margins expand amid aggressive growth | ||
| 08:06 | Yatharth Hospital Q2 FY27 slides: Advent deal fuels 7,000-bed plan | ||
| 08:06 | Endurance Q2 FY27 slides: 34% revenue jump, margin recovery ahead | ||
| 08:06 | Rosenblatt upgrades Navitas Semiconductor stock rating on power demand | ||
| 08:06 | JPMorgan downgrades Ball stock rating to neutral on valuation | ||
| 08:06 | JPMorgan downgrades Crown Holdings stock rating on valuation | ||
| 07:54 | ENIL Q2 FY27 slides: digital grows as radio revenue pressured | ||
| 07:54 | SAMHI Hotels Q2 FY2027 slides: same-store growth tops guidance | ||
| 07:54 | Evercore ISI reiterates Apple stock rating on AI investment outlook | ||
| 07:54 | RBC Capital reiterates Rhythm Pharmaceuticals stock rating on Q3 beat | ||
| 07:54 | Morgan Stanley downgrades Flagstar Bank stock rating on earnings outlook | ||
| 07:54 | Piper Sandler reiterates Apollo Global stock rating on growth outlook | ||
| 07:42 | Aarti Drugs Q2 FY27 slides: record revenue, margins hit 6-year high | ||
| 07:42 | Power Grid Q2 FY27 slides: capex raised, capitalization surges 139% | ||
| 07:42 | Solar Industries Q2 FY27 slides: defence surge drives 69% revenue jump | ||
| 07:42 | Mizuho reiterates Eaton stock rating on strong quarterly results | ||
| 07:42 | Piper Sandler resumes Supernus Pharmaceuticals stock at Overweight | ||
| 07:42 | Piper Sandler reiterates Amneal stock rating on earnings beat | ||
| 07:42 | TD Cowen downgrades Aurora Cannabis stock rating on Organigram deal |